IMFINZI Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer Who Are Treated With Maintenance Therapy After Definitive Chemoradiation Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.